Ad
Search
Generic filters
Filter by content type
Taxonomy terms

TENX – Tenax Therapeutics Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

2

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 4.5

Low: 4

High: 5

Total Analysts: 1

Company Profile

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need. The Company’s products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The Company’s lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for the treatment of pulmonary arterial hypertension (PAH), which is a fatal orphan disease. The Company has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses